N-(4-氨基苄基)-乙酰胺 | 99362-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-氨基苄基)-乙酰胺
• 中文别名: N-[(4-氨基苯基)甲基]醋胺石
• 英文名称: N-(p-aminobenzyl)acetamide
• 英文别名: N-(4-aminobenzyl)acetamide；N-[(4-aminophenyl)methyl]acetamide
• CAS: 99362-10-4
• 化学式: C₉H₁₂N₂O
• mdl: MFCD00195613
• 分子量: 164.207
• InChiKey: QYQYMVAVTKTFEK-UHFFFAOYSA-N

物化性质

• 熔点：
  93-94 °C
• 沸点：
  414.8±28.0 °C(Predicted)
• 密度：
  1.117±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(4-氨基苄基)-乙酰胺 在 sodium hydroxide 作用下， 反应 2.5h， 以86%的产率得到4-氨基苄胺
  参考文献：
  名称：

  pH optimization of nucleophilic reactions in water

  摘要：

  We present a way of prescribing the pH for a reaction so as to obtain either (a) maximum yield in competition with hydrolysis or (b) selective reaction at either of two sites in such nucleophile-electrophile reactions as C-alkylation of acidic ketones and the acylation and sulfonylation of amines. First, we derive the following general equation for pH(max), the pH giving the highest yield of the product (P) of the reaction of a nucleophile (Nu) with a hydrolyzable electrophile (E) in water: pH(max) = 1/2[log (k(w)/k(OH)) + pK(w) + pK(a)] (k(w) and k(OH) refer to the water- and hydroxide-promoted hydrolyses of E, K(w) is the autoprotolysis constant of water, and K(a) is the acid dissociation constant of NuH+, the conjugate acid of Nu). pH(max) thus depends on a property of E (namely, k(w)/k(OH)) and a property of Nu (the pK(a) of NuH+), but not on the rate constant for the reaction of E with Nu or the concentration of Nu. We then deduce analogous approximate equations for maximum selectivity for reaction at either of two nucleophilic sites, specifically, equations giving pH(xmax) and pH(ymax), the pH values for the maximum yields of the respective products (P(x) and P(y)) of the reactions of E with the two nucleophiles. We find that (a) pH-yield profiles calculated from the equations concur with observed yields for reactions under pseudo-first-order conditions and (b) preparative experiments at the estimated pH values give good to excellent yields of clean products and high selectivity in both the C-alkylation and Schotten-Baumann reactions.

  DOI：

  10.1021/ja00034a040
• 作为产物：
  描述：

  N-苄基乙酰胺 在 盐酸 、 tin 作用下， 生成 N-(4-氨基苄基)-乙酰胺
  参考文献：
  名称：

  过氧化钾使苄基酰胺芳香羟基化

  摘要：

  在18冠6醚存在下，N-苄基酰胺与超氧化钾在苯中反应，生成邻羟基和对羟基羟基化产物。提出了该反应的机理，涉及超氧阴离子对酰胺羰基的亲核攻击和底物-超氧化物加合物从苄基亚甲基夺氢。

  DOI：

  10.1016/s0040-4020(01)97990-6

文献信息

• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2832734A1

  公开（公告）日：2015-02-04

  The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等）等的药剂，其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的那样，或其盐。
• Quinazolinone derivatives as inhibitors of homologous recombinase RAD51
  作者：Ambber Ward、Lilong Dong、Jonathan M. Harris、Kum Kum Khanna、Fares Al-Ejeh、David P. Fairlie、Adrian P. Wiegmans、Ligong Liu

  DOI：10.1016/j.bmcl.2017.05.039

  日期：2017.7

  through small molecule inhibition of RAD51, thereby sensitizing tumor cells to DNA damaging irradiation and/or chemotherapy. Here we report structure-activity relationships for a library of quinazolinone derivatives. A novel RAD51 inhibitor (17) displays up to 15-fold enhanced inhibition of cell growth in a panel of TNBC cell lines compared to compound B02, and approximately 2-fold increased inhibition

  RAD51是同源重组DNA修复途径的重要组成部分，在耐药性癌症（包括侵袭性三阴性乳腺癌（TNBC））中过表达。提出的改善患者治疗效果的策略是通过小分子抑制RAD51，从而使肿瘤细胞对DNA破坏性辐射和/或化学疗法敏感。在这里，我们报告喹唑啉酮衍生物库的结构活性关系。与化合物B02相比，新型RAD51抑制剂（17）在一组TNBC细胞系中对细胞生长的抑制作用提高了15倍，对辐射诱导的RAD51灶形成的抑制作用则提高了约2倍。此外，化合物17 显着抑制TNBC细胞对DNA损伤的敏感性，这意味着潜在的靶向疗法可用于癌症治疗。
• Discovery of <i>N</i>-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors
  作者：Shudong Wang、Carol A. Midgley、Frederic Scaërou、Joanna B. Grabarek、Gary Griffiths、Wayne Jackson、George Kontopidis、Steven J. McClue、Campbell McInnes、Christopher Meades、Mokdad Mezna、Andy Plater、Iain Stuart、Mark P. Thomas、Gavin Wood、Rosemary G. Clarke、David G. Blake、Daniella I. Zheleva、David P. Lane、Robert C. Jackson、David M. Glover、Peter M. Fischer

  DOI：10.1021/jm901913s

  日期：2010.6.10

  compounds were in fact potent inhibitors of aurora A and B kinases. It was shown that potency and selectivity of aurora kinase inhibition correlated with the presence of a substituent at the aniline para-position in these compounds. The anticancer effects of lead compound 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine (18; Ki values of 8.0 and 9.2 nM for aurora A and B, respectively)

  通过对我们的激酶导向化合物集合的基于细胞的筛选，我们发现N-苯基-4-(噻唑-5-基)嘧啶-2-胺的一个子集是针对癌细胞系的有效细胞毒剂，抑制有丝分裂组蛋白 H3磷酸化，并导致异常的有丝分裂表型。随后证实，这些化合物实际上是极光 A 和 B 激酶的有效抑制剂。结果表明，极光激酶抑制的效力和选择性与这些化合物中苯胺对位取代基的存在相关。先导化合物4-甲基-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine ( 18 ; K i ) 的抗癌作用极光 A 和 B 的值分别为 8.0 和 9.2 nM) 显示来自有丝分裂失败后的细胞死亡和由于细胞抑制极光 A 和 B 激酶而增加的多倍性。初步体内评估表明，化合物18具有口服生物利用度并具有抗癌活性。化合物18 (CYC116) 目前正在癌症患者中进行 I 期临床评估。
• [EN] 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS<br/>[FR] COMPOSES 1H-INDAZOLE-3-CARBOXAMIDE UTILISES EN TANT QU'INHIBITEURS DE KINASES CYCLINE-DEPENDANTES (CDK)
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2004014864A1

  公开（公告）日：2004-02-19

  The invention provides a compound of the formula (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase: wherein A is a group R2 or CH2-R2 where R2 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; B is a bond or an acyclic linker group having a linking chain length of up to 3 atoms selected from C, N, S and O; R1 is hydrogen or a group selected from SO2Rb,SO2NR7R8,CONR7R8,NR7R9 and carbocyclic and heterocyclic groups having from 3 to 7 ring members; R3, to R9 are defined in the description but excluding the compounds N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide and N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide.

  本发明提供了一种式(I)化合物，用于预防或治疗由细胞周期蛋白依赖性激酶介导的疾病状态或条件：其中A是R2基团或CH2-R2，其中R2是具有3至12个环成员的碳环或杂环基团；B是键或具有最多3个原子（选自C、N、S和O）的链长的不饱和链连接基团；R1是氢或选自SO2Rb、SO2NR7R8、CONR7R8、NR7R9以及具有3至7个环成员的碳环和杂环基团；R3至R9在说明书中定义，但不包括化合物N-[(吗啉-4-基)苯基-1H-吲唑-3-甲酰胺]和N-[4-(乙酰氨基磺酰基)苯基-1H-吲唑-3-甲酰胺]。